东曜药业股份有限公司(“BioDlink International Company Limited”，股票代号：1875)与要约人药明合联生物技术有限公司(“WuXi XDC Cayman Inc.”)联合公布一份白色股份要约接纳及过户表格，涉及每股4.00港元的现金收购方案。相关文件日期为2026年2月12日，并附有香港交易及结算所有限公司及香港联交所等机构的责任声明。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.